NCT00217737 2026-03-18
Oxaliplatin, Leucovorin, and Fluorouracil With or Without Bevacizumab in Treating Patients Who Have Undergone Surgery for Stage II Colon Cancer
National Cancer Institute (NCI)
Phase 3 Active not recruiting
Clinical Trials
26 trialsNCT00980460 2026-03-18
Risk-Based Therapy in Treating Younger Patients With Newly Diagnosed Liver Cancer
National Cancer Institute (NCI)
Phase 3 Active not recruiting
NCT02135042 2026-03-18
Individualized Treatment in Treating Patients With Stage II-IVB Nasopharyngeal Cancer Based on EBV DNA
NRG Oncology
Phase 2/3 Active not recruiting
NCT02997228 2026-03-18
Testing the Addition of Atezolizumab to Combination Chemotherapy or Atezolizumab Alone for Metastatic Colon or Rectal Cancer, the COMMIT Study
National Cancer Institute (NCI)
Phase 3 Active not recruiting
NCT03775265 2026-03-18
Chemoradiotherapy With or Without Atezolizumab in Treating Patients With Localized Muscle Invasive Bladder Cancer
National Cancer Institute (NCI)
Phase 3 Active not recruiting
NCT04083599 2026-03-16
GEN1042 Safety Trial and Anti-tumor Activity in Participants With Malignant Solid Tumors
Genmab
Phase 1/2 Active not recruiting
NCT06607185 2026-03-13
A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
Eli Lilly and Company
Phase 1 Active not recruiting
NCT06704724 2026-03-13
A Study to Learn About the Study Medicine PF-07985045 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Change in a Gene.
Pfizer
Phase 1 Active not recruiting
NCT06011772 2026-03-11
EGF-Depleting Therapy CIMAvax-EGF in Combination With Standard Therapy for RAS- and BRAF Wild-Type Metastatic Colorectal Cancer
Roswell Park Cancer Institute
Phase EARLY_PHASE1 Active not recruiting
NCT05229497 2026-03-09
A Phase Ib/II Study of AK112 in Combination With AK117 in Advanced Malignant Tumors
Akeso
Phase 1/2 Active not recruiting
NCT00707473 2026-03-05
Docetaxel, Cisplatin and Fluorouracil in Treating Patients With Previously Untreated Stage II-IV Nasal Cavity and Paranasal Sinus Cancer
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT02890355 2026-03-05
FOLFIRI or Modified FOLFIRI and Veliparib as Second Line Therapy in Treating Patients With Metastatic Pancreatic Cancer
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT04522336 2026-03-05
Pembrolizumab and Chemoradiotherapy for the Treatment of Unresectable Gastroesophageal Cancer
M.D. Anderson Cancer Center
Phase 1 Active not recruiting
NCT05721755 2026-03-05
Combining Radiation Therapy With Immunotherapy for the Treatment of Metastatic Squamous Cell Carcinoma of the Head and Neck
Eastern Cooperative Oncology Group
Phase 3 Active not recruiting
NCT05568095 2026-03-04
STAR-221
Arcus Biosciences, Inc.
Phase 3 Active not recruiting
NCT05846867 2026-03-04
A Phase Ib/II Clinical Study on AK112 Combined or Not Combined With AK119 in pMMR/MSS Colorectal Cancer
Akeso
Phase 1/2 Active not recruiting
NCT00588770 2026-03-03
Chemotherapy With or Without Bevacizumab in Treating Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
National Cancer Institute (NCI)
Phase 3 Active not recruiting
NCT04094688 2026-03-03
SOLARIS
Alliance for Clinical Trials in Oncology
Phase 3 Active not recruiting
NCT06057038 2026-03-03
A Safety Trial of GEN1042 in Japanese Subjects With Malignant Solid Tumors
Genmab
Phase 1 Active not recruiting
NCT04166318 2026-03-02
Lower-Dose Chemoradiation in Treating Patients With Early-Stage Anal Cancer, the DECREASE Study
Eastern Cooperative Oncology Group
Phase 2 Active not recruiting
NCT04233866 2026-03-02
Comparing Two Treatment Combinations, Gemcitabine and Nab-Paclitaxel With 5-Fluorouracil, Leucovorin, and Liposomal Irinotecan for Older Patients With Pancreatic Cancer That Has Spread
Eastern Cooperative Oncology Group
Phase 2 Active not recruiting
NCT04248452 2026-03-02
Testing the Addition of Radiotherapy to the Usual Treatment (Chemotherapy) for Patients With Esophageal and Gastric Cancer That Has Spread to a Limited Number of Other Places in the Body
Eastern Cooperative Oncology Group
Phase 3 Active not recruiting
NCT05152147 2026-02-27
HERIZON-GEA-01
Jazz Pharmaceuticals
Phase 3 Active not recruiting
NCT05329766 2026-02-27
EDGE-Gastric
Arcus Biosciences, Inc.
Phase 2 Active not recruiting
NCT05891171 2026-02-27
ARC-25
Arcus Biosciences, Inc.
Phase 1 Active not recruiting
NCT04430738 2026-02-24
Tucatinib Plus Trastuzumab and Oxaliplatin-based Chemotherapy or Pembrolizumab-containing Combinations for HER2+ Gastrointestinal Cancers
Seagen Inc.
Phase 2 Active not recruiting